Compare AbCellera Biologics Inc (ABCL) vs Micron Technology, Inc. (MU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Micron Technology, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Micron Technology, Inc. trades at $932.45 (market cap $1.06T). The key difference: Micron Technology, Inc. is far larger — about 451.1× AbCellera Biologics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MU | |
|---|---|---|
Market Cap | $2.35B | $1.06T |
Sector | Health | Technology |
52-Week High | $8.12 | $1.21K |
52-Week Low | $2.78 | $104.88 |
Enterprise Value | $1.99B | $1.04T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Micron Technology (MU) trades at $938.38, down 3.81% amid a sector-wide chip stock selloff, despite strong fundamentals including a 22.84% net margin and three consecutive quarterly earnings beats. The stock shows a bullish technical trend with support near $933, while analyst consensus remains strongly positive with a $1,540 price target. Recent news highlights AI-driven demand and new supply deals with Ford and GM, though competition and cyclicality pose risks.
Outlook is positive given robust earnings growth and AI memory demand, but investors face volatility from memory market cycles and competitive pressures. The stock offers upside to analyst targets if execution continues, yet macroeconomic and sector rotations could drive near-term swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
